Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y5ED
|
||||
| Former ID |
DIB015617
|
||||
| Drug Name |
AV-203
|
||||
| Synonyms |
ErbB3-targeted antibodies (cancer), AVEO/Biogen Idec
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
| Company |
Aveo oncology
|
||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-3 | Target Info | [2] | ||
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| Endocytosis | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | ||||
| ErbB receptor signaling network | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| WikiPathways | ErbB Signaling Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Signaling Pathways in Glioblastoma | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Heart Development | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01603979) A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 2 | Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.